Recalcitrant Pustular Psoriasis Successfully Treated With Adalimumab

Álvarez, Antonio Chaves; Rodríguez-Nevado, Isabel; Argila, D. de; Rubio, Francisco Peral; Rovira, I.; Torrelo, Antonio; Zambrano, Antonio

doi:10.1111/j.1525-1470.2010.01219.x

Cited by 33 publications

(35 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because infliximab has rapid onset of action and high efficacy in GPP, it would be a preferred choice among the available TNF‐α antagonists 2 . Additionally, to our knowledge, the benefits of adalimumab for GPP have not been reported from Japan and only five instances from other countries 3–7 . This scarcity of papers on adalimumab for GPP highlights the significance of our report.…”

mentioning

confidence: 76%

Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis

Kimura¹,

Kinoshita²,

Sekigawa

et al. 2012

The Journal of Dermatology

View full text Add to dashboard Cite

mentioning

confidence: 76%

Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis

Kimura¹,

Kinoshita²,

Sekigawa

et al. 2012

The Journal of Dermatology

View full text Add to dashboard Cite

“…However, because of the short history of use of etanercept, its potential side‐effects after long‐term use are currently unclear. As for adalimumab, some case reports have been published periodically, but the drug has not been used extensively.…”

Section: Chapter V: Strength Of Recommendations and Comments For Eachmentioning

confidence: 99%

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Fujita

Terada

Hayama

et al. 2018

The Journal of Dermatology

192

456

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and systemic flushing accompanied by extensive sterile pustules. The committee of the guidelines was founded as a collaborative project between the Japanese Dermatological Association and the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labour, and Welfare Research Project on Overcoming Intractable Diseases. The aim of the guidelines was to provide current information to aid in the treatment of patients with GPP in Japan. Its contents include the diagnostic and severity classification criteria for GPP, its pathogenesis, and recommendations for the treatment of GPP. Since there are few clinical trial data with high levels of evidence for this rare disease, recommendations by the committee are described in the present guidelines.

show abstract

“…There has been certain experience with the drug in pediatric populations since it was approved by the FDA for JIA treatment (2008), where it is administered subcutaneously at 24 mg/m 2 (max 40 mg) every 2 weeks. Regarding juvenile psoriasis, there are only two published case reports in which adalimumab was prescribed to two adolescent patients with recalcitrant pustular psoriasis at a dose of 40 mg subcutaneously every 2 weeks, after the failure of etanercept and of other conventional systemic agents 69,70. In both cases, there was a favorable outcome 69,70.…”

Section: Management Of Psoriasis In Adolescencementioning

confidence: 99%

“…Regarding juvenile psoriasis, there are only two published case reports in which adalimumab was prescribed to two adolescent patients with recalcitrant pustular psoriasis at a dose of 40 mg subcutaneously every 2 weeks, after the failure of etanercept and of other conventional systemic agents 69,70. In both cases, there was a favorable outcome 69,70. The only long-term safety data we have from the administration of adalimumab to children and adolescents comes from JIA trials, which show its safety profile to be similar to the other anti-TNFα agents 71.…”

Section: Management Of Psoriasis In Adolescencementioning

confidence: 99%

Management of psoriasis in adolescence

Fotiadou¹,

Lazaridou²,

Ioannides³

2014

AHMT

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory cutaneous disorder affecting 2%–4% of the world’s population. The prevalence of the disease in childhood and adolescence ranges between 0.5% and 2%. The management of psoriasis in adolescence is an intriguing and complicated task. Given the paucity of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, physicians must rely on published experience from case reports both from the field of dermatology as well as from the application of these drugs for other pediatric conditions coming from the disciplines of rheumatology, gastroenterology, and oncology. Psoriatic adolescents deal with a potentially disfiguring and lifelong disease that could permanently impair their psychological development. It must be clarified to them that psoriasis does not have a permanent cure, and therefore the main goal of treatments is to establish disease control and prolonged periods between flares. The majority of adolescents suffer from mild psoriasis, and thus they are treated basically with topical treatment modalities. Phototherapy is reserved for adolescents with mild-to-moderate plaque disease and/or guttate psoriasis when routine visits to specialized centers do not create practical problems. Systemic agents and biologics are administered to patients with moderate-to-severe plaque psoriasis, pustular psoriasis, or erythrodermic psoriasis.

show abstract

Recalcitrant Pustular Psoriasis Successfully Treated With Adalimumab

Abstract: We report a 13-year-old girl with severe pustular psoriasis who had an excellent response to treatment with adalimumab after failure with methotrexate, acitretin, cyclosporin, phototherapy, and biologic drugs including etanercept and infliximab.

Cited by 33 publications

References 4 publications

Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis

Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis

Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

Management of psoriasis in adolescence

Contact Info

Product

Resources

About